肝脏NFAT信号调控胆汁淤积中炎症细胞因子的表达
该研究探讨了NFATc3在胆汁酸诱导的肝脏炎症反应中的作用。在人和小鼠原代肝细胞及胆汁淤积肝组织中,NFATc3核转位增加,伴随IL-8、CXCL2、CXCL10表达升高;抑制NFAT活化或敲低Nfatc3可减少胆汁酸驱动的细胞因子诱导,在Abcb4-/-小鼠体内阻断NFAT活化可减轻胆汁淤积性肝损伤。
要点
- 胆汁酸处理使人和小鼠肝细胞中NFATc3核转位增加,并升高IL-8、CXCL2、CXCL10的mRNA水平。
- 抑制NFAT活化或敲低Nfatc3可显著减少小鼠肝细胞中胆汁酸驱动的上述细胞因子诱导。
- 在Abcb4-/-小鼠体内阻断NFAT活化可减轻胆汁淤积性肝损伤。
核心结论
- NFAT在胆汁淤积中胆汁酸刺激的肝脏细胞因子表达中起重要作用。
- 阻断肝脏NFAT活化可能减轻人类的胆汁淤积性肝损伤。
研究设计与样本
- 研究检测了小鼠和人原代肝细胞培养及胆汁淤积肝组织(小鼠模型和原发性胆汁性胆管炎[PBC]或原发性硬化性胆管炎[PSC]患者)中的基因和蛋白表达及细胞定位。
- 采用定量PCR、蛋白质印迹和免疫组织化学评估表达与定位,并在体内和体外使用特异性NFAT抑制剂。
- 采用基因报告分析和染色质免疫沉淀PCR(ChIP-PCR)测定启动子活性。
主要发现
- NFAT亚型c1和c3在人 and 小鼠肝细胞中表达。
- 用胆汁淤积水平的胆汁酸处理时,人和小鼠肝细胞中NFATc3核转位增加,并伴随这些细胞中IL-8、CXCL2和CXCL10的mRNA水平升高。
- 用通路特异性抑制剂阻断NFAT活化或敲低Nfatc3表达,显著减少小鼠肝细胞中胆汁酸驱动的这些细胞因子诱导。
- 在胆汁淤积肝脏中,小鼠模型(胆管结扎或Abcb4-/-小鼠)和PBC及PSC患者中NFATc3/Nfatc3蛋白的核表达增加,分别与小鼠组织Cxcl2水平升高或人组织IL-8水平升高相关。
- 基因报告分析和ChIP-PCR显示,IL-8启动子中的NFAT反应元件在胆汁酸诱导的人IL-8表达中起关键作用;在Abcb4-/-小鼠体内阻断NFAT活化可减轻胆汁淤积性肝损伤。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The nuclear factor of activated T-cells (NFAT) plays an important role in immune responses by regulating the expression of inflammatory genes. However, it is not known whether NFAT plays any role in the bile acid (BA)-induced hepatic inflammatory response. Thus, we aimed to examine the functional role of NFATc3 in cholestatic liver injury in mice and humans. METHODS: Gene and protein expression and cellular localization were assessed in primary hepatocyte cultures (mouse and human) and cholestatic liver tissues (murine models and patients with primary biliary cholangitis [PBC] or primary sclerosing cholangitis [PSC]) by quantitative PCR, western blot and immunohistochemistry. Specific NFAT inhibitors were used in vivo and in vitro. Gene reporter assays and ChIP-PCR were used to determine promoter activity. RESULTS: NFAT isoforms c1 and c3 were expressed in human and mouse hepatocytes. When treated with cholestatic levels of BAs, nuclear translocation of NFATc3 was increased in both human and mouse hepatocytes and was associated with elevated mRNA levels of IL-8, CXCL2, and CXCL10 in these cells. Blocking NFAT activation with pathway-specific inhibitors or knocking down Nfatc3 expression significantly decreased BA-driven induction of these cytokines in mouse hepatocytes. Nuclear expression of NFATc3/Nfatc3 protein was increased in cholestatic livers, both in mouse models (bile duct ligation or Abcb4-/- mice) and in patients with PBC and PSC in association with elevated tissue levels of Cxcl2 (mice) or IL-8 (humans). Gene reporter assays and ChIP-PCR demonstrated that the NFAT response element in the IL-8 promoter played a key role in BA-induced human IL-8 expression. Finally, blocking NFAT activation in vivo in Abcb4-/- mice reduced cholestatic liver injury. CONCLUSIONS: NFAT plays an important role in BA-stimulated hepatic cytokine expression in cholestasis. Blocking hepatic NFAT activation may reduce cholestatic liver injury in humans. LAY SUMMARY: Bile acid induces liver injury by stimulating the expression of inflammatory genes in hepatocytes through activation of the transcription factor NFAT. Blocking this activation in vitro (in hepatocyte cultures) and in vivo (in cholestatic mice) decreased the expression of inflammatory genes and reduced liver injury.
引用
- Cai SY, Yu D, Soroka CJ, et al. Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis. J Hepatol. 2020. PMID: 33039404. doi:10.1016/j.jhep.2020.09.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。